[8-K] ImageneBio, Inc. Reports Material Event

Rhea-AI Filing Summary

ImageneBio, Inc. appointed its Chief Executive Officer, Kristin Yarema, Ph.D., as the company’s interim principal financial officer, effective immediately on October 21, 2025.

The board made the appointment to fill the finance leadership role on an interim basis. Dr. Yarema’s biographical information is incorporated by reference from the “Management” section of the company’s Form S-1 (File No. 333-290108) filed on September 8, 2025.

Insights

Corporate governance analyst

CEO adds interim PFO duties; temporary consolidation of roles.

ImageneBio named CEO Kristin Yarema, Ph.D. as interim principal financial officer on October 21, 2025. This consolidates top executive oversight of operations and finance under one leader while the company covers the finance role on an interim basis.

Such dual-hatting is typically administrative and may streamline decision-making short term. The filing references her background via the September 8, 2025 Form S-1, indicating no new compensation or contract terms were described in this excerpt.

NASDAQ false 0001835579 0001835579 2025-10-21 2025-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c)

On October 21, 2025, the board of directors of ImageneBio, Inc. (the “Company”) appointed Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, as the Company’s interim principal financial officer, effective immediately.

Dr. Yarema’s biographical information is set forth under the section titled “Management” in the Company’s registration statement on Form S-1 (File No. 333-290108), filed with the Securities and Exchange Commission on September 8, 2025, and is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: October 22, 2025				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer

FAQ

What did ImageneBio (IMA) announce?

The board appointed CEO Kristin Yarema, Ph.D. as the company’s interim principal financial officer.

When did the interim PFO appointment at IMA take effect?

The appointment was effective immediately on October 21, 2025.

Does Kristin Yarema remain CEO of ImageneBio?

Yes. She remains Chief Executive Officer while also serving as interim principal financial officer.

Where can I find biographical information on Kristin Yarema?

Her bio is incorporated by reference from the Form S-1 (File No. 333-290108) filed on September 8, 2025.

What is ImageneBio’s stock symbol and listing?

The common stock trades on The Nasdaq Capital Market under the symbol IMA.